[Tumour assessment criteria for immune checkpoint inhibitors].

Related Articles

[Tumour assessment criteria for immune checkpoint inhibitors].

Rev Mal Respir. 2018 Oct;35(8):828-845

Authors: Wasielewski E, Cortot AB

Abstract
The development of immune checkpoint inhibitors in thoracic oncology has led to a reconsideration of the rules for radiological tumor assessment. The RECIST criteria are widely used for the assessment of conventional treatments but are not suitable for anti-tumoral immunotherapy. The mechanism of action of this new class of drugs may induce specific patterns of response, which are not fully assessed by the RECIST criteria. Several new criteria have been proposed to better detect these patterns of response. The changes usually include confirmation of progression, new ways of assessing new lesions, and a larger role for clinical assessment. Nevertheless, harmonization and validation of these criteria remains indispensable. In this review, we will detail the different criteria that are currently available, and discuss their strengths and weaknesses.

PMID: 30166076 [PubMed - indexed for MEDLINE]

from A via a.sfakia on Inoreader http://bit.ly/2Fp7zxs